| Is the use of specialized nutritional formulations a cost‐effective strategy? A national database evaluation A Strickland, A Brogan, J Krauss, R Martindale, G Cresci Journal of Parenteral and Enteral Nutrition 29, S81-S91, 2005 | 99 | 2005 |
| Budget-impact analysis of health care interventions J Mauskopf, SR Earnshaw, A Brogan, S Wolowacz, TH Brodtkorb Springer, 2017 | 49 | 2017 |
| Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States SE Talbird, AJ Brogan, AP Winiarski, B Sander American Journal of Health-System Pharmacy 66 (5), 469-480, 2009 | 40 | 2009 |
| Cost-effectiveness of telaprevir combination therapy for chronic hepatitis C AJ Brogan, SE Talbird, JR Thompson, JD Miller, J Rubin, B Deniz PLoS One 9 (3), e90295, 2014 | 34 | 2014 |
| Non-separation in the mean–lower-partial-moment portfolio optimization problem AJ Brogan, S Stidham Jr European Journal of Operational Research 184 (2), 701-710, 2008 | 29 | 2008 |
| Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach AJ Brogan, SE Talbird, AE Davis, EW Thommes, G Meier Human Vaccines & Immunotherapeutics 13 (3), 533-542, 2017 | 28 | 2017 |
| Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection J Mauskopf, AJ Brogan, SE Talbird, S Martin Aids 26 (3), 355-364, 2012 | 28 | 2012 |
| A note on separation in mean-lower-partial-moment portfolio optimization with fixed and moving targets AJ Brogan, S Stidham Jr Iie Transactions 37 (10), 901-906, 2005 | 27 | 2005 |
| Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity JC Javitt, GP Zlateva, SR Earnshaw, AM Pleil, CN Graham, AJ Brogan, ... Value in Health 11 (4), 563-574, 2008 | 26 | 2008 |
| Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA J Mauskopf, A Brogan, S Martin, E Smets Pharmacoeconomics 28, 83-105, 2010 | 25 | 2010 |
| Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States AJ Brogan, J Mrus, A Hill, AW Sawyer, E Smets HIV clinical trials 11 (3), 133-144, 2010 | 19 | 2010 |
| Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naive adults with HIV infection in the United States AJ Brogan, SE Talbird, C Cohen Value in Health 14 (5), 657-664, 2011 | 17 | 2011 |
| US cost effectiveness of darunavir/ritonavir 600/100mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN trial A Brogan, J Mauskopf, SE Talbird, E Smets Pharmacoeconomics 28, 129-146, 2010 | 15 | 2010 |
| Oseltamivir for influenza postexposure prophylaxis: Economic evaluation for children aged 1–12 years in the US SE Talbird, AJ Brogan, AP Winiarski American journal of preventive medicine 37 (5), 381-388, 2009 | 9 | 2009 |
| The cost-effectiveness and budget impact of ibalizumab-uiyk for adults with multidrug-resistant HIV-1 infection in the United States AJ Brogan, SE Talbird, AE Davis, EM La, PN Kumar PharmacoEconomics 39, 421-432, 2021 | 7 | 2021 |
| Is increased screening and early antiretroviral treatment for HIV‐1 worth the investment? An analysis of the public health and economic impact of improvement in the UK AJ Brogan, SE Talbird, AE Davis, L Wild, D Flanagan HIV medicine 20 (10), 668-680, 2019 | 7 | 2019 |
| Targeted preventive vaccination campaigns to reduce Ebola outbreaks: An individual-based modeling study D Bisanzio, AE Davis, SE Talbird, T Van Effelterre, L Metz, M Gaudig, ... Vaccine 41 (3), 684-693, 2023 | 6 | 2023 |
| Cost‐effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment‐naïve adults with HIV‐1 … E Wilkins, M Fisher, AJ Brogan, SE Talbird, EM La HIV medicine 17 (7), 505-515, 2016 | 6 | 2016 |
| Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada AJ Brogan, E Smets, JA Mauskopf, SAL Manuel, I Adriaenssen Pharmacoeconomics 32, 903-917, 2014 | 6 | 2014 |
| Cost-Effectiveness of darunavir for the management of HIV-infected, treatment-experienced Adults in Canada J Mauskopf, A Brogan, C Malmberg, P Hwang Poster Presented at the 16th Annual Canadian Conference on HIV/AIDS Research, 2007 | 4 | 2007 |
